US FDA rejects Mylan's biosimilar of Amgen's cancer drug - EIU Country Analysis

US FDA rejects Mylan's biosimilar of Amgen's cancer drug

US FDA rejects Mylan's biosimilar of Amgen's cancer drug - EIU Country Analysis
US FDA rejects Mylan's biosimilar of Amgen's cancer drug
Published Oct 12, 2017
257 words — Published Oct 12, 2017
Price US$ 37.00  |  Buy this Report Now

About This Report

  
Brief Excerpt:

The US Food and Drug Administration (FDA) has rejected a marketing application for Mylan NV's biosimilar version of Amgen Inc's Neulasta (pegfilgrastim), its chemotherapy drug, according to a statement by Biocon Ltd, its Indian partner,...

  
Source:
Geography / Regions
India, United States
Industry
Healthcare, Pharmaceuticals and biotechnology
Format:
HTML HTML
Buy Now

EIU Country Analysis—The Economist Intelligence Unit, a division of London's Economist Group, is the most respected provider of country analysis for governments, multi-national corporations and financial institutions around the world. Through our network of over 500 international contributor economists, we establish independent macro-economic outlooks and detailed reports on the political and commercial environments for over 200 countries around the world.

About the Author


Cite this Report

  
MLA:
EIU Country Analysis. "US FDA rejects Mylan's biosimilar of Amgen's cancer drug" Oct 12, 2017. Alacra Store. Dec 15, 2017. <http://news.alacrastore.com/eiu-news/US-FDA-rejects-Mylan-s-biosimilar-of-Amgen-s-cancer-drug-IWHLTH_IWHLTH_MAIN_20171012T170900_0001>
  
APA:
EIU Country Analysis. (). US FDA rejects Mylan's biosimilar of Amgen's cancer drug Oct 12, 2017. New York, NY: Alacra Store. Retrieved Dec 15, 2017 from <http://news.alacrastore.com/eiu-news/US-FDA-rejects-Mylan-s-biosimilar-of-Amgen-s-cancer-drug-IWHLTH_IWHLTH_MAIN_20171012T170900_0001>
  
US$ 37.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.